Padagis LLC was formed following the acquisition of Perrigo Company plc's Rx Division by Altaris Capital. Padagis is a leader in the generic prescription pharmaceutical industry and has more than 1,300 employees across six locations in the United States and Israel. The companys diversified portfolio consists of over 200 product families and 800 SKUs, with a focus on extended topical dosage forms, including creams, ointments, lotions, gels, foams, liquids, and nasal sprays. The company has a long track record of launching first-to-file and first-to-market generic pharmaceutical products that have helped to make prescription products more affordable for patients and reduce costs for the healthcare system. Padagis Pharmaceuticals Israel inherited the operations of Perrigo Israel operating a manufacturing facility in Yeruham in the south of Israel.